Finerenone in patients with severe heart failure: The FINEARTS-HF trial.

aimsWhile patients with severe heart failure (HF) were historically considered to have reduced left ventricular ejection fraction (LVEF), it is increasingly recognized that severe HF occurs across the full spectrum of LVEF. The aim of this study was to assess prevalence, cardiovascular (CV) outcome risk, and treatment response to the non-steroidal mineralocorticoid receptor antagonist finerenone among patients with severe HF in FINEARTS-HF. METHODS AND

resultsTreatment effects of finerenone on the primary endpoint of total (first and recurrent) HF events and CV death were assessed by severe HF status, as defined by the adapted multiparametric ESC-HFA criteria including New York heart Association functional class III/IV, hospitalization for HF within the previous 12 months, and impairment of health status measured by Kansas City Cardiomyopathy Questionnaire total symptom score <75. Overall, 888 (14.8%) patients fulfilled the definition for severe HF. Patients with severe HF were older, with a higher comorbidity burden, and higher N-terminal pro-B-type natriuretic peptide levels. Over a median follow-up of 2.7 years, total HF events and CV death occurred at a higher rate among those with severe HF (31.6 per 100 patient-years [py]) as compared to those without severe HF (13.9 per 100py). Finerenone was beneficial in reducing the rate of the primary endpoint regardless of severe HF status (p

conclusionsAmong patients with mildly reduced or preserved LVEF, severe HF was associated with a heightened risk of CV events. Treatment with finerenone appeared safe and effective, regardless of HF severity.